All In Biotech

Drug Trial Radar · NCT03760003

Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis

A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Dose, Induction Study to Evaluate the Safety, Tolerability and Optimal Dose of ABX464 Compared With Placebo in Patients With Moderate to Severe Ulcerative Colitis Who Have Inadequate Response, Loss of Response, or Intolerance With at Least One of the Following Agents: Immunosuppressant Treatment (i.e. Azathioprine, 6-mercaptopurine, Methotrexate), Tumor Necrosis Factor Alpha [TNF-α] Inhibitors, Vedolizumab, JAK Inhibitors and/or Corticosteroid Treatment

Last checked: Nov 19, 2026Latest source record: Nov 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 355 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

355

Actual

Start

Aug 13, 2019

Primary completion

Apr 1, 2021

Study completion Apr 16, 2021

Sponsor

Lead sponsor
Abivax S.A.Industry
Sponsor type
Industry
First posted
Nov 30, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 2b study to evaluate the efficacy and the safety of 3 dose-levels of ABX464, administered daily in patients with moderate to severe Ulcerative Colitis.

Conditions

  • Ulcerative Colitis

Interventions

  • ABX464 100 mgDrug

    ABX464 100 mg (two capsules of ABX464 50 mg) once daily for 16 weeks

  • ABX464 50 mgDrug

    ABX464 50 mg (one capsule of ABX464 50 mg + one capsule of placebo) once daily for 16 weeks

  • ABX464 25 mgDrug

    ABX464 25 mg (one capsule of ABX464 25 mg + one capsule of placebo) once daily for 16 weeks

  • PlaceboDrug

    Two capsules of placebo once daily for 16 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction From Baseline in Modified Mayo Score (MMS) at Week 8Time frame: Week 8

Locations

130 sites in 17 countries. Site status is shown where the registry gives one.

  • UCSD Health System

    San Diego, California

  • Atlanta Center for Gastroenterology, P.C

    Decatur, Georgia

  • Central Texas Clinical Research, LLC

    Austin, Texas

  • Southern Star Research Institute, LLC

    San Antonio, Texas

  • Medizinische Universität Innsbruck

    Innsbruck, Austria

  • Klinikum Klagenfurt am Wörthersee

    Klagenfurt, Austria

  • Ordensklinikum Linz GmbH - Barmherzige Schwestern

    Linz, Austria

  • AKH - Medizinische Universität Wien

    Vienna, Austria

  • Gomel Regional Clinical Hospital

    Homyel, Belarus

  • Minsk city diagnostic center

    Minsk, Belarus

  • Regional Clinical Hospital

    Minsk, Belarus

  • Vitebsk Regional Clinical Hospital

    Vitebsk, Belarus

  • Vitebsk regoinal clinical specialized center

    Vitebsk, Belarus

  • AZ Sint-Lucas

    Bruges, Belgium

  • C. H. U. St-Pierre

    Brussels, Belgium

  • UZA

    Edegem, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Brandon Medical Arts Clinic

    Brandon, Canada

  • South Edmonton Gastroenterology

    Edmonton, Canada

  • LHSC - Victoria Hospital

    London, Canada

  • The Ottawa Hospital - General Campus

    Ottawa, Canada

  • Allen Whey Khye Lim Professional Corporation

    Saskatoon, Canada

  • Mount Sinai Hospital

    Toronto, Canada

  • Fakultni nemocnice u sv. Anny v Brne

    Brno, Czechia

  • Hepato-Gastroenterologie HK s.r.o.

    Hradec Králové, Czechia

  • MUDr. GREGAR s.r.o.

    Olomouc, Czechia

  • Fakultni nemocnice Ostrava

    Ostrava-Kunčice, Czechia

  • Nemocnice Na Bulovce

    Prague, Czechia

  • Thomayerova nemocnice

    Prague, Czechia

  • Nemocnice Slany

    Slaný, Czechia

  • CHU Amiens - Hopital Sud

    Amiens, France

  • CHU Besançon - Hôpital Jean Minjoz

    Besançon, France

  • CHU Clermont Ferrand - Hôpital d'Estaing

    Clermont-Ferrand, France

  • Hôpital Beaujon

    Clichy, France

  • CHU de Grenoble - Hôpital Nord

    Grenoble, France

  • Centre Hospitalier Départemental Les Oudairies

    La Roche-sur-Yon, France

  • CHU Lille - Hôpital Claude Huriez

    Lille, France

  • Hôpital Nord - CHU Marseille

    Marseille, France

  • Hopital Saint Eloi

    Montpellier, France

Showing 40 of 130 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.